The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1525
July 17, 2017
View Complete Issue         Table of Contents 2019 
Brodalumab (Siliq) - Another IL-17A Antagonist for Psoriasis
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Brodalumab (Siliq) - Another IL-17A Antagonist for Psoriasis
July 17, 2017 (Issue: 1525)
The FDA has approved brodalumab (Siliq – Valeant), an injectable human interleukin (IL)-17A receptor antagonist, for treatment of adults with moderate to severe plaque psoriasis who have failed to respond to other systemic therapies. Brodalumab...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Brodalumab (Siliq) - Another IL-17A Antagonist for Psoriasis
Article code: 1525b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.